Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2020
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2020
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 10 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinsons Disease, Neurodegenerative Diseases, Crohns Disease (Regional Enteritis), Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Hypertension and Solid Tumor.
Furthermore, this report also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 10 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Oncology and Ophthalmology which include indications Parkinsons Disease, Neurodegenerative Diseases, Crohns Disease (Regional Enteritis), Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Hypertension and Solid Tumor.
Furthermore, this report also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AbbVie Inc, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Avalyn Pharma Inc, H2 2020
Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Pipeline by Fratagene Therapeutics Srl, H2 2020
Pipeline by Lead Discovery Center GmbH, H2 2020
Pipeline by Prous Institute for Biomedical Research SA, H2 2020
Pipeline by TopiVert Ltd, H2 2020
Pipeline by Turning Point Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AbbVie Inc
AstraZeneca Plc
Avalyn Pharma Inc
Boehringer Ingelheim International GmbH
Fratagene Therapeutics Srl
Lead Discovery Center GmbH
Prous Institute for Biomedical Research SA
TopiVert Ltd
Turning Point Therapeutics Inc
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AbbVie Inc, H2 2020
Pipeline by AstraZeneca Plc, H2 2020
Pipeline by Avalyn Pharma Inc, H2 2020
Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Pipeline by Fratagene Therapeutics Srl, H2 2020
Pipeline by Lead Discovery Center GmbH, H2 2020
Pipeline by Prous Institute for Biomedical Research SA, H2 2020
Pipeline by TopiVert Ltd, H2 2020
Pipeline by Turning Point Therapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
List Of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
RELATED REPORTS
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Drugs In Development, 2021
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Drugs In Development, 2021Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22
View ReportNACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3) - Drugs in Development, 2021
NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain
View ReportLeucine Rich Repeat Serine/Threonine Protein Kinase 2 - Drugs In Development, 2021
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Drugs In Development, 2021Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22
View ReportNACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3) - Drugs in Development, 2021
NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
